Annual report pursuant to Section 13 and 15(d)

Selected Balance Sheet Information

v3.6.0.2
Selected Balance Sheet Information
12 Months Ended
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Balance Sheet Disclosures [Text Block]
4. Selected Balance Sheet Information
 
Prepaid expenses and other current assets (in thousands):
 
 
 
December 31,
 
December 31,
 
 
 
2016
 
2015
 
Prepaid clinical research organizations
 
$
1,677
 
$
8,329
 
Prepaid insurances
 
 
358
 
 
339
 
Other prepaid expenses
 
 
295
 
 
208
 
Other receivables
 
 
185
 
 
-
 
Intrexon prepaid research and development expenses
 
 
-
 
 
643
 
 
 
 
 
 
 
 
 
Total
 
$
2,515
 
$
9,519
 
 
The Intrexon prepaid research and development expenses were classified as a current asset at December 31, 2015. As of December 31, 2016, the Company had applied all of the Intrexon prepaid research and development expenses to research and development expenses.
  
Prepaid clinical research organization expense is classified as a current asset. The Company makes payments to the clinical research organizations based on agreed upon terms that includes payments in advance of study services. The Company anticipates that the majority of the prepaid clinical research organization expenses will be applied to research and development expenses during 2017.
 
Property and equipment (in thousands):
 
 
 
December 31,
 
December 31,
 
 
 
2016
 
2015
 
Computer and office equipment
 
$
641
 
$
346
 
Software
 
 
11
 
 
11
 
Leasehold improvements
 
 
439
 
 
242
 
 
 
 
1,091
 
 
599
 
Less accumulated depreciation and amortization
 
 
(186)
 
 
(105)
 
 
 
 
 
 
 
 
 
Total
 
$
905
 
$
494
 
 
Accrued expenses (in thousands):
 
 
 
December 31,
 
December 31,
 
 
 
2016
 
2015
 
Accrued manufacturing costs
 
$
14
 
$
-
 
Accrued vendor payments
 
 
400
 
 
133
 
Accrued clinical consulting  services
 
 
2,211
 
 
164
 
Other accrued expenses
 
 
2
 
 
-
 
 
 
 
 
 
 
 
 
Total
 
$
2,627
 
$
297